IP Library Patent Application 17198157
Patent Application
App. No. 17/198,157

COMBINATION THERAPIES WITH DISULFIRAM

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/198,157
Abstract

Disclosed herein are compositions and methods for increasing lifespan, for preventing or treating a disease including an aging-related disorder, for reducing a symptom of aging, and/or boosting an immune system in a mammal. Also disclosed herein are compositions and methods for improving effectiveness of a vaccine in a mammal. The compositions comprise, at least, a therapeutically effective amount of disulfiram and one or more additional ingredients.

Claims (17)

1 .- 20 . (canceled)

21 . A method for inhibiting and/or reducing pyroptotic cell death in a cell, the method comprising contacting the cell with an active agent that is disulfiram and a potentiating ingredient that is cinnamaldehyde, thereby inhibiting and/or reducing pyroptotic cell death.

22 . The method of claim 21 , wherein disulfiram and cinnamaldehyde are included in one composition and the composition comprises disulfiram and cinnamaldehyde.

23 . The method of claim 21 , wherein the method comprises contacting the cell with a first composition comprises disulfiram and contacting the cell with a second composition comprising cinnamaldehyde.

24 . The method of claim 21 , wherein inhibiting and/or reducing pyroptotic cell death in the cell increases the lifespan of the cell.

25 . The method of claim 21 , wherein the amount of disulfiram is from about 5 mg to about 500 mg and the amount of cinnamaldehyde is from about 0.01% to about 45% by weight of disulfiram.

26 . The method of claim 21 , wherein the cinnamaldehyde further potentiates disulfiram's ability to treat acute lung injury (ALI), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, dry eye, actinic keratosis, alopecia, and/or skin cancer.

27 . The method of claim 21 , wherein the cinnamaldehyde further potentiates disulfiram's ability to inhibit and/or reduce a pathological inflammatory response, alter a T-cell's age, and/or alter mitochondrial function in the cell.

28 . A method for boosting activity of an immune cell, the method comprising contacting the immune cell with an active agent that is disulfiram and a potentiating ingredient that is cinnamaldehyde, thereby boosting activity of the immune cell.

29 . The method of claim 28 , wherein disulfiram and cinnamaldehyde are included in one composition.

30 . The method of claim 28 , wherein the method comprises contacting the immune cell with a first composition comprising disulfiram and contacting the cell with an at least second composition comprising cinnamaldehyde.

31 . The method of claim 28 , wherein boosting activity of the immune cell increases an effective immune response against an infectious agent and/or an atypical cell.

32 . The method of claim 28 , wherein boosting activity of the immune cell improves the immune cell's response against a component contained in a vaccine, wherein the component contained in the vaccine is an antigen obtained from, related to, homologous to, or expressed by an infectious agent.

33 . The method of claim 28 , wherein boosting activity of the immune cell comprises inhibiting a pathological immune response.

34 . The method of claim 33 , wherein boosting activity of the immune cell minimizes overactive immune cell activity.

35 . The method of claim 28 , wherein the amount of disulfiram is from about 5 mg to about 500 mg and the amount of cinnamaldehyde is from about 0.01% to about 45% of the weight of the disulfiram.

36 . A composition comprising an active agent that is disulfiram and a potentiating ingredient that is cinnamaldehyde, wherein the amount of disulfiram is from about 5 mg to about 500 mg and the amount of cinnamaldehyde is from about 0.01% to about 45% of the of the disulfiram.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENTS THAT WERE INADVERTENTLY ENTERED UNDER "APPLICATION" INSTEAD OF "PATENT" IN 4 PATENTS WHEN RECORDING ASSIGNMENT. CORRECTION IS BEING SUBMITTED TO LIST PATENT NUMBER INSTEAD APPLICATION NUMBER PREVIOUSLY RECORDED ON REEL 71147 FRAME 544. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 31, 2025
From: SPRING DISCOVERY, INC.
To: WINTER ACQUISITION SUB, INC.
Reel/Frame 072308/0361 →
NON-EXCLUSIVE LICENSE AGREEMENT AND RIGHT TO PROSECUTE UNDER SECTION (3.1) Recorded May 19, 2025
From: WINTER ACQUISITION SUB, INC.
To: GENENTECH, INC.
Reel/Frame 071300/0456 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2025
From: SPRING DISCOVERY, INC.
To: WINTER ACQUISITION SUB, INC.
Reel/Frame 071147/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2021
From: JACOBSON, RACHEL; COUSIN, WENDY; NGUYEN, AN; PLOTT, TEMPEST; VAN TRUMP, WILLIAM; NGUYEN, DAT; CHEN, DANIEL; HEINRICH, JARRED; KOMALO, BEN; NICOLAISEN, LAUREN; ELABD, CHRISTIAN
To: SPRING DISCOVERY, INC.
Reel/Frame 056236/0050 →